Powered by
ROCHESTER–Caeregen Therapeutics announced that it has been awarded a $1.4 million Phase 2 Small Business Innovation Research grant from the National Institutes of Health and its National Eye Institute to …
WEST BLOOMFIELD TWP.–LSPedia, a software-as-a-service provider specializing in product traceability for the pharmaceutical industry, announced a strategic partnership with Pharmsource, a wholesale distributor in Sunrise, Fla. This collaboration aims to …
LAKELAND–Abionyx Pharma, a startup biotech company with operations in Michigan and France, announced its strategy in ophthalmology and new positive preclinical results in two technological platforms: apotherapy and biovectorisation. Cyrille …
CANTON TWP.-TrialAssure, a software-as-a-service provider for pharmaceutical clinical trials, announced the release of a new and improved trial results disclosure system, TrialResults.com. Company officials said the new site provides improved …
CANTON TWP.–MMS Holdings, a contract research organization for the pharmaceutical industry, announced the addition of Philip Breitfeld and Bernhardt Zeiher to its board of scientific advisors. Both industry leaders in …
GRAND RAPIDS–Corium Pharma Solutions Inc., a contract development and manufacturing organization serving the prescription drug and consumer products industries, has named Suzanne Hincliffe as Chief People Officer. This announcement follows …
GRAND RAPIDS–Corium Pharma Solutions Inc., a contract developemnt and manufacturing firm providing new delivery technologies for prescription drugs and consumer products, has named Kevin Ostrander chief business officer and Niraj …
CANTON TWP.–MMS Holdings, a contract research organization, announced an expansion of its leadership team with the appointment of Chris Schoonmaker as COO and Ashu Tandon as chief commercial officer. Both Schoonmaker and Tandon …
GRAND RAPIDS–Cancer & Hematology Centers of Western Michigan has launched a cancer drug repository program to accept qualified unused oral cancer drug donations from individuals so they can be used …
LAKELAND–Abionyx Pharma reported that the pilot Phase 2a clinical trial evaluating its drug candidate CER-001, the only natural recombinant apoA-I, as a treatment for septic patients at high risk of …